Cargando…

Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals

OBJECTIVE: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD. STUDY DESIGN: We performed a retrospective cohort study in infants with severe BPD admitted to United States children’s hospitals. We measured cumulative medication e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamat, Nicolas A., Kirpalani, Haresh, Feudtner, Chris, Jensen, Erik A., Laughon, Matthew M., Zhang, Huayan, Monk, Heather M., Passarella, Molly, Lorch, Scott A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713592/
https://www.ncbi.nlm.nih.gov/pubmed/31227785
http://dx.doi.org/10.1038/s41372-019-0415-9
_version_ 1783446893618003968
author Bamat, Nicolas A.
Kirpalani, Haresh
Feudtner, Chris
Jensen, Erik A.
Laughon, Matthew M.
Zhang, Huayan
Monk, Heather M.
Passarella, Molly
Lorch, Scott A.
author_facet Bamat, Nicolas A.
Kirpalani, Haresh
Feudtner, Chris
Jensen, Erik A.
Laughon, Matthew M.
Zhang, Huayan
Monk, Heather M.
Passarella, Molly
Lorch, Scott A.
author_sort Bamat, Nicolas A.
collection PubMed
description OBJECTIVE: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD. STUDY DESIGN: We performed a retrospective cohort study in infants with severe BPD admitted to United States children’s hospitals. We measured cumulative medication exposures in individual subjects and between-center variation after adjustment for infant characteristics. We then identified the specific medications and therapeutic classes with the highest rates of use. RESULTS: In 3252 subjects across 43 hospitals, we identified a median (interquartile range) of 30 (17– 45) cumulative medication exposures per infant. The adjusted mean number of medication exposures varied between centers (p < 0.0001), with a range of 22 – 50. Diuretics and furosemide were the most frequently prescribed therapeutic class and specific medication for the management of severe BPD. CONCLUSIONS: Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center.
format Online
Article
Text
id pubmed-6713592
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-67135922019-12-21 Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals Bamat, Nicolas A. Kirpalani, Haresh Feudtner, Chris Jensen, Erik A. Laughon, Matthew M. Zhang, Huayan Monk, Heather M. Passarella, Molly Lorch, Scott A. J Perinatol Article OBJECTIVE: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD. STUDY DESIGN: We performed a retrospective cohort study in infants with severe BPD admitted to United States children’s hospitals. We measured cumulative medication exposures in individual subjects and between-center variation after adjustment for infant characteristics. We then identified the specific medications and therapeutic classes with the highest rates of use. RESULTS: In 3252 subjects across 43 hospitals, we identified a median (interquartile range) of 30 (17– 45) cumulative medication exposures per infant. The adjusted mean number of medication exposures varied between centers (p < 0.0001), with a range of 22 – 50. Diuretics and furosemide were the most frequently prescribed therapeutic class and specific medication for the management of severe BPD. CONCLUSIONS: Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center. 2019-06-21 2019-09 /pmc/articles/PMC6713592/ /pubmed/31227785 http://dx.doi.org/10.1038/s41372-019-0415-9 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Bamat, Nicolas A.
Kirpalani, Haresh
Feudtner, Chris
Jensen, Erik A.
Laughon, Matthew M.
Zhang, Huayan
Monk, Heather M.
Passarella, Molly
Lorch, Scott A.
Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals
title Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals
title_full Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals
title_fullStr Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals
title_full_unstemmed Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals
title_short Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals
title_sort medication use in infants with severe bronchopulmonary dysplasia admitted to united states children’s hospitals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713592/
https://www.ncbi.nlm.nih.gov/pubmed/31227785
http://dx.doi.org/10.1038/s41372-019-0415-9
work_keys_str_mv AT bamatnicolasa medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals
AT kirpalaniharesh medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals
AT feudtnerchris medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals
AT jensenerika medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals
AT laughonmatthewm medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals
AT zhanghuayan medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals
AT monkheatherm medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals
AT passarellamolly medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals
AT lorchscotta medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals